97582-88-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(Difluoromethoxy)benzonitrile is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(Difluoromethoxy)benzonitrile serves as an intermediate for the production of pesticides and other agrochemicals. Its incorporation into these products can enhance their effectiveness in protecting crops and managing pests, thereby supporting agricultural productivity and food security.

InChI:InChI=1/C8H5F2NO/c9-8(10)12-7-3-1-2-6(4-7)5-11/h1-4,8H

Upstream product

• 97603-92-4 3-Difluoromethoxy-benzaldehyde oxime 
• 620-24-6 3-Hydroxybenzyl alcohol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 873-62-1 m-cyanophenol 
• 530-62-1 1,1'-carbonyldiimidazole 
• 125903-81-3 (3-(difluoromethoxy)phenyl)methanol 
• 85684-61-3 3-(difluoromethoxy)-benzaldehyde 

Downstream Products

• 97603-96-8 3-Difluoromethoxy-benzamidine; hydrochloride 
• 875916-54-4 3-difluoromethoxyisobutyrophenone 
• 1079911-30-0 {5-[5-(3-difluoromethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-2-methyl-phenyl}-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 

Relevant academic research and scientific papers

Decarboxylative Trifluoromethylating Reagent [Cu(O2CCF3)(phen)] and Difluorocarbene Precursor [Cu(phen)2][O2CCF2Cl]

This article describes the new economic decarboxylative trifluoromethylating reagent [Cu(phen)(O2CCF3)] (1; phen=1,10-phenanthroline) and the efficient difluorocarbene precursor [Cu(phen)2][O2CCF2Cl] (2). Treatment of copper tert-butoxide with phen and subsequent addition of trifluoroacetic acid or chlorodifluoroacetic acid afforded air-stable complexes 1 and 2, respectively, which were characterized by X-ray crystallography. The copper(I) ion in 1 is coordinated by a bidentate phen ligand, a monodentate trifluoroacetate group, and a molecule of CH3CN in a distorted tetrahedral coordination geometry. The molecular structure of 2 adopts an ionic form that consists of a [Cu(phen)2]+ cation and a chlorodifluoroacetate anion. Complex 1 reacted with a variety of aryl and heteroaryl halides to form trifluoromethyl (hetero)arenes in good yields. The corresponding Hammett plot exhibited a linear relationship and a reaction parameter (ρ)=+0.56±0.02, which indicated that the trifluoromethylation reaction proceeded via a nucleophilic reactive species. Complex 2 reacts with phenols to produce aryl difluoromethyl ethers in modest-to-excellent yields. Mechanistic investigations revealed that the difluoromethylation reaction proceeds by initial copper-mediated formation of difluorocarbene and subsequent concerted addition of difluorocarbene to the phenol to form a three-center transition state.

Method for synthesis of aryl difluoromethyl ethers

This invention relates to a method for preparing difluoromethyl ethers, thiols and amines without using chlorofluorocarbon gases. The intermediates prepared by this method can be used to make certain compounds which act as PDE IV inhibitors which are useful for treating asthma and other diseases implicated with the PDE IV isozyme.

Preparation of Triazolopyrimidines as Potential Antiasthma Agents

With the use of the human basophil histamine release assay, 5-aryl-2-aminotriazolopyrimidines were found to be active as mediator release inhibitors.These compounds were prepared by reacting arylamidines with sodium ethyl formylacetate or with ethyl propiolate to give pyrimidinones.Treatment with phosphorus oxychloride gave a chloropyrimidine, which was converted to a hydrazinopyrimidine with hydrazine.Cyclization, using cyanogen bromide, gave the triazolopyrimidines, after a Dimroth rearrangement.Following a structure-activity evaluation, the5--2-amino (8-10), 5-(3-bromophenyl)-2-amino (8-13), 5--2-amino (8-11), and 5-(4-pyridinyl)-2-amino (6-7) compounds were found to have the best activity.They were chosen for further pharmacological and toxicological study.

5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines

This invention is concerned with 5-substituted[1,2,4]triazolo[1,5-c]pyrimidin-2-amines selected from those of Formula I, which are active as antiasthma agents.